April 19, 2021, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) a clinical-stage biopharmaceutical company focused on discovering and developing innovative targeted and immuno-oncology therapies, today announced the appointment of Dr. Zhen Zhang as CMC VP. He will report to Dr. Yao-Chang Xu, Chairman and CEO of Abbisko.

Dr. Zhang has 20 years of experience in pharmaceutical industry with strong expertise and proven track records in small molecule CMC product development. Prior to joining Abbisko, Dr. Zhang held a R&D director position in Janssen Pharmaceutical. Dr. Zhang led the strategy design and execution of Janssen CMC early development as well as the collaboration with key CROs and leading research institutes in China. Dr. Zhang held several senior management positions in top-notch multi-national pharmaceutical companies and CROs before joining Janssen, including Wythe, Chempartner, and BMS. He has successfully managed CMC development of more than 20 compounds at different developmental stage. Dr. Zhang accumulated deep understanding of CMC development and broad knowledge of other key aspects of drug development.

Dr. Zhang completed his postdoctoral research at the Department of Chemistry in Yale University. Prior to that, he obtained his Ph.D. in Bio-Organic Chemistry from Rutgers, the State University of New Jersey and B.S. degree in Organic Chemistry from Nanjing University.

“We are pleased to have Dr. Zhang join Abbisko to start the next stage of his career.” said Dr. Yao-Chang Xu, “He is a highly experienced leader in CMC development in the pharmaceutical industry. He brings to us strong skills to lead multidisciplinary and diverse teams, rich experience in strategy and operation, and a strong entrepreneurial mindset.”

Dr. Zhang said, "I am greatly impressed with Abbisko’s integrated discovery platform built up by the experienced team with proven track record and expertise, as well as the highly diversified and innovative pipeline. I look forward to working with the dedicated team to help build on the successes achieved to date and accelerate the next phase of the company's explosive growth.”